Please login to the form below

Not currently logged in
Email:
Password:

MHLW

This page shows the latest MHLW news and features for those working in and with pharma, biotech and healthcare.

Bayer roll-out of haemophilia drug Jivi gathers pace

Bayer roll-out of haemophilia drug Jivi gathers pace

Japan’s MHLW is next to approve the drug. Bayer has added another big market for its new haemophilia A product Jivi, adding approval in Japan to a green light in ... Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Jivi (damoctocog

Latest news

  • MSD’s Keytruda wins bladder cancer indication in Japan MSD’s Keytruda wins bladder cancer indication in Japan

    Bladder cancer patients living in Japan can now access Merck Sharp and Dohme’s (MSD) Keytruda (pembrolizumab) following a green light from the Japanese Ministry of Health, Labour and Welfare (MHLW).

  • Ono faces steep price cut for Opdivo in Japan Ono faces steep price cut for Opdivo in Japan

    The MHLW committee has accelerated that process by activating an emergency provision that allows earlier cuts for big-selling drugs – making 100bn to 150bn yen a year – and which exceed company

  • Japanese approvals for GSK, AZ and Bayer Japanese approvals for GSK, AZ and Bayer

    MHLW gives Nucala, Tagrisso and Xofigo the green light. Japan's drug regulator has approved a flurry of new medicines, including GlaxoSmithKline's asthma therapy Nucala and cancer drugs from AstraZeneca ... The Ministry of Health, Labour and Welfare (MHLW

  • Takeda's once-weekly DPP-4 inhibitor cleared in first market Takeda's once-weekly DPP-4 inhibitor cleared in first market

    GlaxoSmithKline (GSK) has been given the go-ahead by the MHLW to market its long-acting muscarinic antagonist (LAMA) Encruse (umeclidinium) for chronic obstructive pulmonary disease (COPD). ... Amgen/Astellas' PCSK9-targeting antibody Repatha (evolocumab)

  • Novartis' Japanese subsidiary threatened with suspension Novartis' Japanese subsidiary threatened with suspension

    The company is staying tight-lipped about the reasons for the unusual action by the Ministry Of Health, Labour and Welfare (MHLW), although it has confirmed it has received a

More from news
Approximately 2 fully matching, plus 20 partially matching documents found.

Latest Intelligence

  • Country report: The healthcare market in Japan Country report: The healthcare market in Japan

    Ministry of Health, Labour and Welfare (MHLW) data revealed that the largest single cause of death was cancer, followed by stroke and heart disease. ... Additionally, if sales of a new drug are greater than estimated by the manufacturer, then its price

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
PRMA Consulting Ltd

PRMA Consulting is an independent consultancy solving some of the most challenging pricing, reimbursement and market access issues facing international...

Latest intelligence

My MS journey: one patient's search for innovation
David Lazarus charts his journey from initial MS diagnosis in 1990 to his experience participating in innovative clinical trials, along with his advice for other patients....
Biotech profile: Tom Evans, CEO, Vaccitech.
Can UK company be first to develop a universal flu vaccine?...
The social dilemma: is it time for pharma to join the party?
Chris Ross explores why social media still isn’t trending for pharma, and how it can join in the fun...

Infographics